The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact.

purpose of reviewThis review explores the clinical applications of PSMA-PET/CT in patients with intermediate to high-risk prostate cancer, focusing on its role in diagnostic reassessment, therapeutic redirection, and potential survival benefits. By evaluating its translational pathway, we aim to provide a structured analysis of its impact on patient management and treatment outcomes. RECENT

findingsProstate cancer remains a significant health challenge, and advancements in imaging techniques such as PSMA-PET/CT have shown promise in improving diagnostic accuracy and guiding treatment decisions. Emerging evidence highlights its superior sensitivity and specificity compared to conventional imaging, facilitating better staging, detection of metastases, and therapy selection. However, challenges persist in standardizing clinical applications, integrating findings into treatment guidelines, and addressing economic considerations. This review synthesizes the latest research findings and cost-effectiveness analyses to establish a comprehensive translational framework for PSMA-PET/CT in prostate cancer management. By consolidating diverse evidence, we aim to provide the medical community with clearer insights into its clinical utility, address ongoing controversies, and propose strategies to minimize treatment risks. The conclusions drawn from this study aspire to refine treatment protocols and enhance clinical outcomes for patients with this prevalent malignancy.